Pillar Biosciences Closes $29.7 Million in Series C Financing

Financing to Advance IVD and RUO Product Development and to Expand Global Commercialization Natick, MA, May 5, 2020—Pillar Biosciences, an NGS clinical cancer diagnostics company, today announced the closing of a $29.7 million Series C preferred stock financing. The financing will accelerate the expansion of Pillar’s in vitro diagnostic and research use only panels and …

Pillar Biosciences Closes $29.7 Million in Series C Financing Read More »